LinkedIn image ad examples

𝗗𝗲𝘇𝗲 𝗶𝗻𝘀𝗰𝗵𝗿𝗶𝗷𝗳𝗿𝗼𝗻𝗱𝗲 𝘀𝗹𝘂𝗶𝘁 𝗼𝗽 𝟭𝟲 𝗻𝗼𝘃𝗲𝗺𝗯𝗲𝗿, 𝟭𝟮:𝟬𝟬. Met een jaarlijkse rente van 8% en een looptijd van 4 jaar, biedt deze investering een uitstekende kans om uw kapitaal te laten groeien terwijl u bijdraagt aan een nobel doel. U investeert in levensreddende apparaten en helpt bij het plaatsen van meer AED's. Wilt u meer informatie ontvangen? Vraag vrijblijvend de brochure aan! Beleggen brengt risico's met zich mee. U kunt uw inleg verliezen. Lees het Basisprospectus op https://lnkd.in/eR5HJdqY voordat u een beleggingsbeslissing neemt.

𝗜𝗻𝘃𝗲𝘀𝘁𝗲𝗲𝗿 𝗶𝗻 𝗹𝗲𝘃𝗲𝗻𝘀𝗿𝗲𝗱𝗱𝗲𝗻𝗱𝗲 𝘁𝗲𝗰𝗵𝗻𝗼𝗹𝗼𝗴𝗶𝗲 𝗺𝗲𝘁 𝗣𝘂𝗹𝘀𝗲𝟰𝗮𝗹𝗹.📈 Met onze obligatie-uitgifte kunt u bijdragen aan de uitbreiding van AED-netwerken, cruciaal bij hartstilstanden. Zo behaalt u een rendement van 8% per jaar op uw investering. En iemand anders een mooi rendement op het leven. Investeren kan vanaf € 1.000. Meer informatie ontvangen? Ontvang vrijblijvend de brochure en ontdek hoe deze investering werkt. Beleggen brengt risico's met zich mee. U kunt uw inleg verliezen. Lees het Basisprospectus op https://lnkd.in/eR5HJdqY voordat u een beleggingsbeslissing neemt.

How to stop fragmented assay development staling your projects? Multiple readouts per run means fewer runs, faster time to insight, faster decisions and increased ROI. FIDA closes data gaps by delivering 3 measurements directly in complex matrices with no purification, on sample volumes down to 2 µL. Imagine studying binding affinity or kinetics in the context of your sample characteristics, all done in 1 run? It is possible thanks to 3 simultaneous measurements and embedded sample characterisation readouts – all in 1 run. Fewer assays, fewer compromises. What is FIDA? Flow induced dispersion analysis is an in-solution biophysical technology based on first-principle physics. It resolves molecular size, binding and sample characteristics from one diffusion profile — replacing a stack of complementary assays with a single experiment, under native conditions. →Watch a webinar about Fida Evolve -> the new generation of FIDA.

Does surface immobilisation distort the dynamics you're trying to measure? Every FIDA measurement happens in laminar flow, in the native sample environment. That removes surface regeneration cycles, non-specific binding artefacts and lengthy assay development, and it lets you work directly in complex matrices such as serum, plasma, cell lysate and fermentation media — no purification required, across a full range of detergent conditions. All this, in native, in-solution conditions for increased biological relevance. What is FIDA? Flow induced dispersion analysis is an in-solution biophysical technology based on first-principle physics. It resolves molecular size, binding and sample characteristics from one diffusion profile — replacing a stack of complementary assays with a single experiment, under native conditions. → Watch a webinar about Fida Evolve -> the new generation of FIDA

Medical Affairs is evolving. Expectations are rising. Explore what a different approach to HCP engagement can deliver. Discover EPIKAST at epikast.com.

👉 Het gebruik van up-to-date software is niet langer alleen een IT-beslissing: het is een strategische keuze, met name voor anatomopathologische laboratoria. Nu de diagnostische complexiteit steeds verder toeneemt en de druk op de teams alleen maar groter wordt, hebben laboratoria software nodig die niet alleen aan hun huidige behoeften voldoet, maar ook aan die van de toekomst... en die hen tegelijkertijd klaarstoomt voor de toekomst. Vanuit deze visie bieden wij u de nieuwste versie van Clinisys™ DaVinci aan. Met deze versie kunt u: - Vol vertrouwen werken op een stabiele en moderne basis - Efficiënt en samenhangende pathologische workflows gebruiken - Te profiteren van de koppeling tussen de pathologische, moleculaire en beeldvormingsomgevingen - Aan te sluiten bij de diagnostische en operationele eisen van de pathologische activiteiten - U voor te bereiden op toekomstige ontwikkelingen in de workflows, met zo min mogelijk verstoring van uw dagelijkse werkzaamheden. En aangezien een update niet alleen uit nieuwe functies bestaat, hebben we ervoor gezorgd dat Clinisys™ DaVinci u kan blijven ondersteunen bij uw klinische, operationele en digitale uitdagingen, terwijl het tegelijkertijd als basis fungeert voor uw toekomstige behoeften.

In June, the FDA issued draft guidance that could mark a new era in drug development. 📃🔬 One robust pivotal trial, supported by confirmatory evidence, is re-emerging as a pathway for establishing drug effectiveness, shifting the focus away from the long-standing “two-trial dogma.” But this shift also changes the questions sponsors should be asking. Not simply “how many trials are needed?” but “what combination of rigorous clinical and confirmatory evidence will persuasively demonstrate effectiveness?” In our latest white paper with Cytel, Jurgen Hummel, Evie Merinopoulou, and I explore: 1. The critical factors that make a single pivotal trial persuasive 2. How sponsors can prospectively plan for regulatory-grade confirmatory data including real-world evidence 3. Why relying more heavily on a single pivotal trial raises the evidentiary stakes for the entire development program Learn more in the full white paper via the link below 👇 https://lnkd.in/g7enQpUW

𝗪𝗲 𝗷𝘂𝘀𝘁 𝗰𝗼𝗺𝗽𝗹𝗲𝘁𝗲𝗱 𝘁𝗵𝗲 𝗳𝘂𝗹𝗹 𝗮𝗰𝗾𝘂𝗶𝘀𝗶𝘁𝗶𝗼𝗻 𝗼𝗳 𝗺𝗔𝗯𝘅𝗶𝗲𝗻𝗰𝗲. 𝗧𝗵𝗶𝘀 𝗺𝗮𝗿𝗸𝘀 𝘁𝗵𝗲 𝗻𝗲𝘅𝘁 𝗺𝗶𝗹𝗲𝘀𝘁𝗼𝗻𝗲 𝗶𝗻 𝗯𝘂𝗶𝗹𝗱𝗶𝗻𝗴 𝗮 𝗹𝗲𝗮𝗱𝗶𝗻𝗴, 𝘃𝗲𝗿𝘁𝗶𝗰𝗮𝗹𝗹𝘆 𝗶𝗻𝘁𝗲𝗴𝗿𝗮𝘁𝗲𝗱 𝗕𝗶𝗼𝗽𝗵𝗮𝗿𝗺𝗮 𝗯𝘂𝘀𝗶𝗻𝗲𝘀𝘀 𝗮𝘁 𝘀𝗰𝗮𝗹𝗲. Full ownership of mAbxience gives us complete control over cost, capacity and launch timing, as well as the full economic benefit, as the next wave of biologics loses exclusivity. For patients, that means dependable access to high-quality biosimilars; for shareholders, it is a disciplined investment in a business we know well. The transaction builds on a successful partnership that began with our initial investment in mAbxience four years ago and has already delivered important development, manufacturing, technology-transfer and regulatory achievements. We want to build on this momentum. The acquisition of the remaining stake in mAbxience is therefore an important milestone on our #FutureFresenius journey. It strengthens our Biopharma business, which has performed exceptionally well in recent years and is gradually becoming a true earnings powerhouse. The biosimilars market is one of the most exciting and dynamic areas in healthcare. These biologics enable highly effective treatment at affordable prices, making these medicines more accessible, particularly for chronically and critically ill patients with cancer or autoimmune diseases. We are seeing more and more healthcare systems around the world embrace biosimilars – and we want to help shape this development for the benefit of patients. A very special thank you to mAbxience CEO Jurgen Van Broeck and his team for the excellent collaboration over the past few years and for their entrepreneurial drive and scientific expertise. We look forward to continuing this journey together and are delighted to welcome the mAbxience team to Fresenius Group. My thanks also go to Dr. Sang-Jin Pak and the Biopharma team at Fresenius Kabi, who have set new standards for relevance and innovation in recent years. Keep it up! #Biosimilars #FutureFresenius #FreseniusCommittedToLife

Dein Investment für Gesundheit & Wachstum 📈 6 % Fixzins p.a. mit 5 Jahren Laufzeit. 🏭 Unterstütze die weitere Expansion von BIOGENA: Mit neuen BIOGENA PLAZAs, dem Ausbau unserer Präsenz in Österreich, Deutschland und Italien sowie dem Aufbau unseres Apothekenvertriebs wollen wir Gesundheit noch näher zu den Menschen bringen. ➡️ Informiere dich jetzt! Disclaimer: Werbung gemäß Art. 22 ProspektVO. Details im Prospekt unter https://lnkd.in/eD_GU5B9. Kein Angebot, keine Kaufaufforderung. Anlage mit Risiko. **Die 6% Anleihe Biogena GmbH & Co KG 2026-2031 kann in Österreich u.U. für den GEWINNFREIBETRAG herangezogen werden.

Just two weeks to go until the 21st Annual Biomarkers, CDx & Precision Medicine Europe 2026 in Basel! Excited for Patholytix Research Services to showcase how we combine subspecialist pathology expertise, digital infrastructure and AI to support biopharma partners across biomarker development, translational research and clinical trials. We also have a packed speaking programme: 🎤 Day 1 | 14:30 | Track 9 – Computational Pathology, Image Analysis & AI Pierre Moulin, Chief Scientific Officer Building the Future of Pathology AI: Foundation Models for Clinical Trials and CDx Pierre will explore next-generation foundation models for biomarker discovery, CDx development and clinical trials, alongside our newly launched CipherX. 🎤 Day 1 | 16:50–17:00 | Data & AI Zone Pierre Moulin, Chief Scientific Officer Mining Archival Biopsies for Progression Biomarkers in MASLD Using CipherX 🎤 Day 2 | 09:40 | Track 3 – Biomarkers in Translational & Clinical Development Georgia Cresswell, Commercial Lead, Research Services Scaling Expert Pathology: Global Networks Meet Bespoke AI for Pharma Partners Georgia will discuss how global pathology expertise and bespoke AI can help pharma partners scale pathology across translational and clinical programmes. 🎤 Day 2 | 13:00–13:30 | Conference Room 7 Pierre will also join the panel discussion, Deploying Computational Pathology Across the Pharma Pipeline, exploring real-world implementation across pharma R&D. Meet Colin Doolan, Pierre Moulin, Georgia Cresswell, Stéphane BORGHESE and Anita F. Dulberg in the Congress Centre Basel at booth 68. We look forward to seeing you there! #BIOMEU2026 #Patholytix #Biomarkers #CompanionDiagnostics #PrecisionMedicine #DigitalPathology

Dein Investment für Gesundheit & Wachstum 📈 6 % Fixzins p.a. mit 5 Jahren Laufzeit. 🏭 Unterstütze die weitere Expansion von BIOGENA: Mit neuen BIOGENA PLAZAs, dem Ausbau unserer Präsenz in Österreich, Deutschland und Italien sowie dem Aufbau unseres Apothekenvertriebs wollen wir Gesundheit noch näher zu den Menschen bringen. ➡️ Informiere dich jetzt! Disclaimer: Werbung gemäß Art. 22 ProspektVO. Details im Prospekt unter https://lnkd.in/eD_GU5B9. Kein Angebot, keine Kaufaufforderung. Anlage mit Risiko. **Die 6% Anleihe Biogena GmbH & Co KG 2026-2031 kann in Österreich u.U. für den GEWINNFREIBETRAG herangezogen werden.

🧬Service Spotlight: Oligonucleotide therapeutics continue to gain momentum, with more products reaching the market and pipelines expanding across targets and indications. To support this growing field, BioDuro builds on its established small-molecule discovery experience to deliver an integrated oligonucleotide discovery platform that connects specialized siRNA design, oligo chemistry and conjugation, biological evaluation, and oligo-specific bioanalysis. Whether you’re exploring new oligonucleotide candidates or advancing promising leads, download the flyer for a closer look at the platform: https://lnkd.in/eYP9-dHq #Oligonucleotides #siRNA #DrugDiscovery #DMPK #Biology #DidcoveryChemistry

👉 Utiliser des logiciels à jour ce n'est plus seulement une décision IT : c'est faire un choix stratégique, notamment pour les laboratoires d'anatomo-pathologie. Alors que la complexité diagnostique ne cesse d’augmenter et que la pression sur les équipes ne fait qu’évoluer, les laboratoires ont besoin de logiciels qui les accompagnent sur leurs besoins du moment mais aussi ceux à venir... tout en se tenant prêts pour l'avenir. C’est dans cette démarche que nous vous proposons la dernière version de Clinisys™ DaVinci. Cette version vous permettra de : - Travailler en toute confiance sur une base stable et moderne ; - Utiliser des workflows d'anatomie pathologique efficaces et cohérents ; - Bénéficier de la connectivité entre les environnements d'anatomie pathologique, moléculaires et d'imagerie ; - Rester alignés sur les exigences diagnostiques et opérationnelles de l'activité anapath ; - Vous préparer aux évolutions futures des workflows, avec le moins de perturbations possibles sur vos opérations du quotidien. Et comme une mise à jour ce n'est pas QUE des nouvelles fonctionnalités, nous avons fait le nécessaire pour que Clinisys™ DaVinci puisse continuer à servir vos défis cliniques, opérationnels et numériques tout en servant de socle de base pour vos besoins à venir. 📄 En savoir + : https://lnkd.in/ehzWV55k #Anatomopathologie #InformatiqueDeLaboratoire #SantéNumérique #ITSanté #Clinisys

DC Klinieken Dokkum | Nascholing voor huisartsen | 2 november Tijdens deze interactieve nascholing delen onze specialisten actuele inzichten over pijnzorg, endoscopie en lage rugklachten. Praktische kennis die je direct kunt toepassen in de dagelijkse praktijk. ✅ 3 accreditatiepunten aangevraagd ✅ Inclusief dinerbuffet ✅ Gratis deelname Schrijf je nu in!

Cross-market comparison without harmonising several sources yourself first. Run GPI alongside what you use today, at no charge.

A dedicated Customer Success Manager and a 24 hour response on data queries. Run GPI alongside what you use today.

¿Eres nefrólogo/a y te gustaría revisar los avances más recientes en el abordaje de la enfermedad renal crónica? La nueva edición de la jornada "Puesta al día en Nefrología", coordinada por las Dras. Raquel Ojeda, Mª Dolores Martínez y Mercedes Salgueira, reúne a expertos de referencia de toda España para debatir los principales retos en el abordaje de la ERC. 🗓️ 19-20 noviembre 📍 Hotel Barceló, Málaga 👉 Inscríbete: https://lnkd.in/e6kS-Ysm 🤝 Avalado por la Sociedad Andaluza de Nefrología.

🏆 A proud moment for HarmonyRx! It’s official! Joseph N. Savasta, CEO of HarmonyRx, has received the 2026 PBMI Innovator of the Year Award. This recognition celebrates Joe’s leadership, vision and commitment to challenging the traditional pharmacy benefit model and building a better approach centered on transparency, clinical integrity and long-term value. Joe has remained focused on a simple belief: pharmacy benefits can and should work better for employers, members and the people who serve them. We’re incredibly proud to see that commitment recognized by the industry. Congratulations, Joe, on this well-deserved honor! 👏 🎥Watch the moment: https://lnkd.in/e-xiHiAY/?utm_campaign=Boost_Post_Engagement_Oct1,2026&utm_source=linkedin&utm_medium=paid&utm_id=1215605504&hsa_acc=519040050&hsa_cam=1215605504&hsa_grp=901212894&hsa_ad=1585226164&hsa_net=linkedin&hsa_ver=3 #HarmonyRx #PBMI2026 #InnovatorOfTheYear #PharmacyBenefits #PBM #PBO #HealthcareInnovation #Leadership

What should brands consider when developing their next mobility solution? The MyCondro™ infographic presents key information about chondroitin, differentiation and mobility innovation in one concise resource. Download it to explore the opportunity.

DC Klinieken Alkmaar | Nascholing voor huisartsen | 2 november Tijdens deze interactieve nascholing op 2 november in Alkmaar delen onze specialisten praktische inzichten over diagnostiek, behandeling en verwijsmogelijkheden bij (hoofd)pijn. ✅ 3 accreditatiepunten ✅ Inclusief dinerbox ✅ Gratis deelname Schrijf je nu in!

Growing your aligner volume requires more than setting a target. Use the Aligner Volume Planning Worksheet to map your expected growth and identify what needs to be ready for it.

We’re looking for a Senior Organisational Development Consultant to join Helping Hand and help shape how our people, leaders and teams thrive. This is a strategic role focused on organisational effectiveness, workforce capability, culture, employee experience and leading meaningful change. You’ll partner with leaders across the organisation, use workforce insights to identify opportunities, and design practical solutions that make a difference. If you’re an experienced OD professional who enjoys influencing, facilitating and turning strategy into action, we’d love to hear from you. Apply now: https://lnkd.in/e8dKwuNR

I’m no genie… but here’s a sneak peek into your future with Orbit. You know exactly which grants fit your stage and country. You have a pulse on where health tech capital is moving. You get negotiated rates on the services you need, without the hours of work. You have the decks, models and playbooks you need, right at your fingertips. Your calendar keeps you ahead of the European health tech ecosystem, with the conferences, investor days and founder meetups that actually matter to you. That’s Orbit. Less searching. Less guesswork. More time to build your product and reach the patients that need it. The first 100 sign-ups get €10/month, locked in for life. No contract. No onboarding call. No sales sequence. Just join, explore and leave anytime.

Met jouw financiële kennis en scherpe blik kun je een belangrijke bijdrage leveren aan onderzoek naar borst-, baarmoederhals- en darmkanker.